CN1931239B - Chinese medicine prepn for treating hepatitis B - Google Patents
Chinese medicine prepn for treating hepatitis B Download PDFInfo
- Publication number
- CN1931239B CN1931239B CN2006100951375A CN200610095137A CN1931239B CN 1931239 B CN1931239 B CN 1931239B CN 2006100951375 A CN2006100951375 A CN 2006100951375A CN 200610095137 A CN200610095137 A CN 200610095137A CN 1931239 B CN1931239 B CN 1931239B
- Authority
- CN
- China
- Prior art keywords
- radix
- hepatitis
- weight portions
- chinese medicine
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a Chinese medicine preparation for treating hepatitis B. The Chinese medicine preparation has effective components prepared with the materials including ginseng: 200-300 weight portions, glossy ganoderma: 200-300 weight portions, schisandra: 250-350 weight portions, gentian root: 400-600 weight portions, root of Tonkin sophora: 400-600 weight portions, isatis root: 900-1100 weight portions and licorice: 2900-3100 weight portions. It may be prepared into various pharmaceutically acceptable preparation forms, such as capsule, tablet, bolus and granule. The invention has the functions of strengthening body' immunity, protecting liver cell, promoting rehabilitation of liver function, antagonizing hepatitis B virus, etc and thus possesses high hepatitis B curing rate.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation, particularly a kind of Chinese medicine preparation for the treatment of hepatitis B.
Background technology
Chronic persistent disease that hepatitis B virus causes that hepatitis B is an organism infection.Nearly 1.2 hundred million populations are hepatitis b virus carrier in China, and wherein about 10% develops into chronic hepatitis, and this disease course of disease is long, and can develop into liver cirrhosis even hepatocarcinoma.Treat the medicine of hepatitis B at present, effects such as Western medicine such as interferon, lamivudine are all not obvious, and toxic and side effects is big.Many Chinese medicine preparation are also arranged, but can promote liver function recovery, hepatitis B surface antigen, e antigen, core antibody to turn out cloudy, the medicine that produces surface antibody but seldom, and curative effect all is unsatisfied with.It as application number a kind of medicine for the treatment of hepatitis B of 02139021.5, have and regulate and activate body immune system and remove hepatitis B virus, hold concurrently with the effect that protects the liver, promotes that hepatocyte recovers, turn out cloudy with surface antigen, e antigen, producing surface antibody and liver function recovery normally is standard, and cure rate only can reach 38%.
Summary of the invention
The purpose of this invention is to provide a kind of energy enhancing human body immunity power, promote liver function recovery, promote surface antigen, e antigen, core antibody to turn out cloudy, impel surface antibody to produce, improve the Chinese medicine preparation of cure rate.Concrete technical scheme is as follows:
A kind of Chinese medicine preparation for the treatment of hepatitis B is characterized in that wherein making that raw materials of effective components is formed and weight proportion is: Radix Ginseng 200～300 Ganodermas 200～300 Fructus Schisandrae Chinensis 250～350 Radix Gentianaes 400～600 Radix Sophorae Tonkinensiss 400～600 Radix Isatidis 900～1100 Radix Glycyrrhizaes 2900～3100.
Wherein the preferred weight proportion of each raw material is: Radix Ginseng 220～280 Ganodermas 230～280 Fructus Schisandrae Chinensis 270～320 Radix Gentianaes 450～550 Radix Sophorae Tonkinensiss 460～560 Radix Isatidis 960～1050 Radix Glycyrrhizaes 2950～3020.
Wherein the optimum weight proportioning of each raw material is: Radix Ginseng 250 Ganodermas 250 Fructus Schisandrae Chinensis 300 Radix Gentianaes 500 Radix Sophorae Tonkinensiss 500 Radix Isatidis 1000 Radix Glycyrrhizaes 3000.
Above weight proportion is umber.Get the various raw materials in the above-mentioned limited range, oven dry is ground into fine powder powder and can directly takes after mixing it with water with boiled water, each 15 grams of being grown up, and the child is cut down according to the circumstance, every day 4 times, the March course of treatment.
This medicament also can be made on any pharmaceutics said dosage form such as capsule, tablet, pill, granule etc. with the routine techniques of pharmaceutical industry.
The various raw materials of the present invention are the Chinese herbal medicine of pure natural, contain multiple pure natural effective ingredient, as panoxadiol, panaxatriol, erythricine, gentiopicrin, various alkaloid, aminoacid, glycyrrhizin etc., the energy enhancing body weakens the effect of some toxin to body to the defence capability of various destructive stimuluses; Strengthen Tissue respiration, the zymolysis of promotion saccharide improves energy metabolism, makes reticuloendothelial system superfunction, to protective effect and other effects of liver, can alleviate hepatitis symptom and thoroughly treat hepatitis B.To metabolic influence, can influence carbohydrate metabolism, promote the hepatic glycogen heteroplasia, accelerate hepatic glycogen and decompose, the parkerizing process of fructose and glucose is strengthened, can improve the level of blood glucose and blood lactic acid.Antibiosis and antiviral functions.This medicine is absorbed the back and is decomposed into glycyrrhizic acid and glucuronic acid in liver, can combine with poisonous substance and detoxify.Based on above-mentioned pharmacological action, medicine of the present invention has following effect:
1, have stronger anti-HBV effect, inducing interferon and enhancing NK cytoactive, the protection hepatocyte promotes surface antigen (HBsAg), e antigen (HBeAg), three of core antibodies (HBcAb) to turn out cloudy, and impels surface antibody (HBsAb) to form.
2. strengthen the immunocompetence of human body body, activate natural killer cell, promote the vigor of macrophage, activated mononuclear macrophage, T lymphocyte, bone-marrow-derived lymphocyte and NK cell, and can suppress the RNA of virus by stimulating T lymphocytic emiocytosis r-IFN, the proteic translation of blocking virus reaches the purpose that suppresses hbv replication, thereby thoroughly eliminate hepatitis B virus, help the recovery of liver function.
The present invention's prescription is prolonged and repeated the groping of applicant's process, and constantly summary draws, and through clinic trial.Random collecting 100 routine hepatitis B cases, diagnostic criteria is: hepatitis B two double and HBV-DNA are looked in blood drawing, be said clinically great three positive or small three positive, abnormal liver function also shows as the rising in various degree of glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT, and the HBV-DNA fluorescent quantitation raises.Man's 57 examples, women 43 examples, the age is between 8 years old～57 years old.Take the prepared powder of the present invention, boiled water is taken after mixing it with water, each 15 grams, and every day 4 times, in the March course of treatment, the stop using medicine of other all treatment hepatitis B of period in a medicine is checked These parameters after treating a course of treatment.
The clinical treatment result:
1.e antigen (HBeAg), core antibody (HBcAb) negative conversion rate are 95%, surface antigen (HBsAg), e antigen (HBeAg), three of core antibodies (HBcAb) are turned out cloudy and surface antibody (HBsAb) is positive reaches 85%.
2. thoroughly killing and eliminate hepatitis B viruses (HBV)-DNA check result is 89%, and hepatitis B viruses (HBV)-DNA reaches normal value or is 99% less than normal value.
All patient's clinical symptoms such as weak, poor appetite, detest wet goods and all obtain in various degree improvement.
The invention has the beneficial effects as follows energy enhancing human body immunity power, protection hepatocyte; promote liver function recovery, and stronger anti-hepatitis virus is arranged, suppress the effect of hbv replication; promote surface antigen, core antibody, e antigen to turn out cloudy, impel surface antibody to produce and improve cure rate.
Specific embodiment (totally 2 examples)
Embodiment 1 takes by weighing various raw materials (unit: restrain) by following prescription: Radix Ginseng 250 Ganodermas 250 Fructus Schisandrae Chinensis 300 Radix Gentianaes 500 Radix Sophorae Tonkinensiss 500 Radix Isatidis 1000 Radix Glycyrrhizaes 3000, and oven dry, pulverizing is powder, and sealing is preserved.
Patient Chen Chiguo, the man, 35 years old, group lamp village, Xiao Xing township, Zhou Jia town, Dianjiang County, Chongqing City, it is preceding on April 10th, 2000 venous blood samples inspection liver function and other indexs to take medicine, take the powder that said medicine is made, boiled water is taken after mixing it with water, each 15 grams, every day 4 times, in the March course of treatment, the stop using medicine of other all treatment hepatitis B of period in a medicine is checked corresponding index after treat a course of treatment.
The result is as follows before and after taking medicine:
(1), liver function total bilirubin 78.44 (15.6) umol/L, bilirubin direct 44.3 (3.5) umol/L, glutamate pyruvate transaminase 436 (38) U/L, glutamic oxaloacetic transaminase, GOT 321 (30) U/L.(data in the bracket are the result after treating)
The every index of treatment back liver function transfers to normally.
(2), hepatitis B is two double
Before the treatment: HBsAg (+) is anti--and HBs (-) HBeAg (+) is anti--the anti-HBc of Hbe (-) (+)
Treatment back: HBsAg (-) is anti--and HBs (+) HBeAg (-) is anti--the anti-HBc of Hbe (-) (-)
Be great three positive before the treatment, treat back three and turn out cloudy, and produce surface antibody.
(3), hepatitis B viruses (HBV)-DNA fluorescent quantitative measurement 8.17 * 10
7Copy/ml, treatment back check 0 copy/ml.
Embodiment 2 takes by weighing various raw materials (unit: restrain) by following prescription: Radix Ginseng 280 Ganodermas 240 Fructus Schisandrae Chinensis 320 Radix Gentianaes 480 Radix Sophorae Tonkinensiss 500 Radix Isatidis 950 Radix Glycyrrhizaes 2900, and oven dry, pulverizing is powder, and sealing is preserved.
Patient Zhao Sisi, the woman, 8 years old, rain mountain village, Zhou Jia town, Dianjiang County, Chongqing City, it is preceding on May 6th, 2000 venous blood samples inspection liver function and other indexs to take medicine, take said medicine powder, boiled water is taken after mixing it with water, each 10 grams, every day 4 times, in the March course of treatment, the stop using medicine of other all treatment hepatitis B of period in a medicine is checked These parameters after treating a course of treatment.
The result contrasts as follows before and after taking medicine:
(1), liver function total bilirubin 19 (16) umol/L, bilirubin direct 6 (4.74) umol/L, glutamate pyruvate transaminase 25 (24) U/L, GOT2 9 (27) U/L (data in the bracket for treatment after result)
(2), hepatitis B is two double
Before the treatment: HBsAg (+) is anti--and HBs (-) HBeAg (-) is anti--the anti-HBc of Hbe (+) (+)
Treatment back: HBsAg (+) is anti--and HBs (-) HBeAg (-) is anti--the anti-HBc of Hbe (-) (-)
Being small three positive before the treatment, all turns out cloudy except that surface antigen in the treatment back.
(3), hepatitis B viruses (HBV)-DNA fluorescent quantitative measurement 2.57 * 10
8Copy/ml, treatment back check 100 copy/ml.
Claims (3)
1. Chinese medicine preparation for the treatment of hepatitis B is characterized in that wherein making that raw materials of effective components is formed and weight proportion is: Radix Ginseng 200～300 Ganodermas 200～300 Fructus Schisandrae Chinensis 250～350 Radix Gentianaes 400～600 Radix Sophorae Tonkinensiss 400～600 Radix Isatidis 900～1100 Radix Glycyrrhizaes 2900～3100.
2. the Chinese medicine preparation of treatment hepatitis B as claimed in claim 1, the weight proportion of wherein making each raw material of effective ingredient is: Radix Ginseng 220～280 Ganodermas 230～280 Fructus Schisandrae Chinensis 270～320 Radix Gentianaes 450～550 Radix Sophorae Tonkinensiss 460～560 Radix Isatidis 960～1050 Radix Glycyrrhizaes 2950～3020.
3. the Chinese medicine preparation of treatment hepatitis B as claimed in claim 1, the weight proportion of wherein making each raw material of effective ingredient is: Radix Ginseng 250 Ganodermas 250 Fructus Schisandrae Chinensis 300 Radix Gentianaes 500 Radix Sophorae Tonkinensiss 500 Radix Isatidis 1000 Radix Glycyrrhizaes 3000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100951375A CN1931239B (en) | 2006-09-20 | 2006-09-20 | Chinese medicine prepn for treating hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100951375A CN1931239B (en) | 2006-09-20 | 2006-09-20 | Chinese medicine prepn for treating hepatitis B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1931239A CN1931239A (en) | 2007-03-21 |
| CN1931239B true CN1931239B (en) | 2011-08-03 |
Family
ID=37877361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100951375A Expired - Fee Related CN1931239B (en) | 2006-09-20 | 2006-09-20 | Chinese medicine prepn for treating hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1931239B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1383881A (en) * | 2002-05-23 | 2002-12-11 | 刘民安 | Gansukang capsule |
| CN1679910A (en) * | 2005-02-04 | 2005-10-12 | 深圳市泰康制药有限公司 | Medicine for treating acute and chronic hepatitis |
-
2006
- 2006-09-20 CN CN2006100951375A patent/CN1931239B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1383881A (en) * | 2002-05-23 | 2002-12-11 | 刘民安 | Gansukang capsule |
| CN1679910A (en) * | 2005-02-04 | 2005-10-12 | 深圳市泰康制药有限公司 | Medicine for treating acute and chronic hepatitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1931239A (en) | 2007-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1698812A (en) | Pharmaceutical composition for treating hepatitis B | |
| CN102389496B (en) | Chinese medical composition for treating hepatitis and preparation method thereof | |
| CN1931239B (en) | Chinese medicine prepn for treating hepatitis B | |
| CN101574494B (en) | Drug for treating hepatitis B | |
| CN100460010C (en) | Chinese medicine composition for treating hepatitis B and viral hepatitis | |
| CN1059104C (en) | Capsule for anti hepatitis B | |
| CN1202820C (en) | Subprostrate sophora oral preparation, preparing method and use | |
| CN1679910A (en) | Medicine for treating acute and chronic hepatitis | |
| CN101618156A (en) | Medicine composition for treating hepatitis B and preparation method thereof | |
| CN1176123A (en) | Medicine for chronic hepatitis B and its preparation | |
| CN101099850B (en) | Medicine composition for treating chronic active hepatitis and early-stage hepatocirrhosis and preparation method thereof | |
| CN1169570C (en) | Medicine for treating acute and chronic hepatitis B | |
| CN1190229C (en) | Medicine for curing hepatitis B | |
| CN1047944C (en) | Capsule for curing hepatitis | |
| CN1176673C (en) | Compound and powder prescription | |
| CN1660282A (en) | Combination of medication for treating hepatitis B and preparation method | |
| CN105079172A (en) | Traditional Chinese medicine composition for treating acute and chronic hepatitis B and cirrhosis | |
| CN1208084C (en) | Chinese patent medicine for curing chronix virus B hepatitis and its preparation method | |
| CN100443096C (en) | Medicine for treating hepatitis B and its preparing process | |
| CN101700342B (en) | Pharmaceutical composition for treating hepatitis B and preparation method thereof | |
| CN1049834C (en) | Medicine for curing hepatitis and its prepn process | |
| CN1133452C (en) | Chunren liver recovering capsule | |
| CN1110588A (en) | Hepatitis B powder medicine and its production method | |
| CN102178789B (en) | Hepatitis B virus resistant traditional Chinese medicine composition and preparation method thereof | |
| CN1197673A (en) | Chinese medicine 'Xiaoyangtang' for curing acute and chronic hepatitis B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110803 Termination date: 20140920 |
|
| EXPY | Termination of patent right or utility model |